{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:13Z","timestamp":1790666953718,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["16398"],"award-info":[{"award-number":["16398"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clml.2015.11.008","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T11:30:18Z","timestamp":1448969418000},"page":"18-28.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-7386","authenticated-orcid":false,"given":"Rena","family":"Buckstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Piliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Ghorab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shuoprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.11.008_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2015.11.008_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.11.008_bib3","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib4","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/asheducation-2011.1.515","article-title":"Therapies for peripheral T-cell lymphomas","volume":"2011","author":"Savage","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2015.11.008_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/asheducation-2008.1.39","article-title":"Does high-dose therapy and autologous hematopoietic stem cell transplantation have a role in the primary treatment of peripheral T-cell lymphomas? ASH evidence-based review 2008","author":"Shustov","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2015.11.008_bib7","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib8","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (CDw52)","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.clml.2015.11.008_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in\u00a0vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.11.008_bib11","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib12","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/10428190290021597","article-title":"Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"43","author":"McCune","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.11.008_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib17","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib18","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A\u00a0pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib19","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.clml.2015.11.008_bib20","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.11.008_bib21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.2007.06689.x","article-title":"Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report","volume":"138","author":"Miles","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.11.008_bib22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib23","series-title":"The Design of Clinical Trials. Clinical Trials in Oncology","first-page":"48","author":"Green","year":"2003"},{"key":"10.1016\/j.clml.2015.11.008_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2015.11.008_bib25","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1080\/10428190802475303","article-title":"Pharmacokinetics of alemtuzumab and the relevance in clinical practice","volume":"49","author":"Elter","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.11.008_bib26","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.11.008_bib27","article-title":"Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with t-lymphoid neoplasms","volume":"108","author":"Ravandi-Kashani","year":"2006","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.clml.2015.11.008_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity","volume":"30","author":"Kim","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2015.11.008_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A\u00a0phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"51","author":"Weidmann","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.11.008_bib30","article-title":"A\u00a0pilot trial of campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies","volume":"106","author":"Janik","year":"2005","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.clml.2015.11.008_bib31","article-title":"Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma","volume":"108","author":"Intragumtornchai","year":"2006","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.clml.2015.11.008_bib32","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial","volume":"92","author":"Binder","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.11.008_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2015.11.008_bib34","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2008-02-138800","article-title":"EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"112","author":"Kluin-Nelemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib36","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4110.4110","article-title":"First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant","volume":"118","author":"d'Amore","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib38","unstructured":"Grady T, Nelson M, Staub A, et\u00a0al. Elevated peripheral blood (PB) cytomegalovirus (CMV) viral loads and reduced CD8+ T cell counts are common findings in T-cell lymphoma before initiation of therapy. Blood\u00a01062005."},{"key":"10.1016\/j.clml.2015.11.008_bib39","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.008_bib40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2008.282","article-title":"Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy","volume":"23","author":"Hwang","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.11.008_bib41","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.11.008_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2008.07028.x","article-title":"Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma","volume":"141","author":"Cox","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.11.008_bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0609.2008.01129.x","article-title":"Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab","volume":"81","author":"Oki","year":"2008","journal-title":"Eur J Hematol"},{"key":"10.1016\/j.clml.2015.11.008_bib44","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2010.108","article-title":"Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma","volume":"24","author":"Porrata","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.11.008_bib45","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","article-title":"Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma","volume":"21","author":"Kim","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.11.008_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.4-5-370","article-title":"T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review","volume":"4","author":"Mackall","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2015.11.008_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hon.947","article-title":"Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab","volume":"29","author":"Kurokawa","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2015.11.008_bib48","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.leu.2404014","article-title":"Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism","volume":"20","author":"Mone","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.11.008_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.11.008_bib50","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2013.086207","article-title":"A\u00a0phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"98","author":"Brown","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.11.008_bib51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2010.033159","article-title":"Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia","volume":"96","author":"Montagna","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.11.008_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.11.008_bib53","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.11.008_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10428190601016167","article-title":"CD52 expression in non-mycotic T- and NK\/T-cell lymphomas","volume":"48","author":"Chang","year":"2007","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T03:44:45Z","timestamp":1599882285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015013786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S2152265015013786"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}